Good ideas and conversation. No ads, no tracking. Login or Take a Tour!
Like every other -omics area, it seems to be still maturing and -omics primarily in name. Sadly these things do not give in situ, single-cell, temporally sliced measurements, and the benchmark most methods developers use is "how many different proteins do we see?"... which is a number that is always increasing. Then you add isoforms and combinations of covalent modifications into the mix and it's anyone's game with plenty of room to grow. But I'm happy with it being a maturing field, means there's lots of sub-optimal areas to do work. Hoping to take b_b's advice and not apply it to cancer if I can help it. Plenty of other diseases that are also interesting and not quite as saturated.